Regeneron Lands a $450 Million "Warp Speed" Contract for Its Prospective COVID-19 Treatment

Regeneron Lands a $450 Million "Warp Speed" Contract for Its Prospective COVID-19 Treatment

The funding will help the biotechnology company ramp up mass production of REGN-COV2 at less financial risk before clinical trials reveal whether it works.